Prudential Financial Inc. acquired a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 11,020 shares of the biotechnology company’s stock, valued at approximately $38,000.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Camden Capital LLC purchased a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter worth about $52,000. Bank of Montreal Can raised its position in BioCryst Pharmaceuticals by 86.6% during the fourth quarter. Bank of Montreal Can now owns 19,898 shares of the biotechnology company’s stock valued at $68,000 after acquiring an additional 9,236 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new position in BioCryst Pharmaceuticals during the fourth quarter valued at approximately $307,000. Charles Schwab Investment Management Inc. lifted its holdings in BioCryst Pharmaceuticals by 45.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 835,249 shares of the biotechnology company’s stock valued at $2,882,000 after acquiring an additional 259,443 shares during the period. Finally, Victory Capital Management Inc. lifted its holdings in BioCryst Pharmaceuticals by 50.0% in the fourth quarter. Victory Capital Management Inc. now owns 25,927 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 8,646 shares during the period. Institutional investors and hedge funds own 89.04% of the company’s stock.
A number of equities research analysts have recently commented on BCRX shares. Needham & Company LLC reaffirmed a “hold” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, March 9th. Zacks Investment Research upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a research note on Monday, March 9th. BidaskClub downgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, March 19th. Finally, ValuEngine upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, December 3rd. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the stock. BioCryst Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $8.38.
Shares of BCRX stock opened at $1.91 on Friday. BioCryst Pharmaceuticals, Inc. has a 1-year low of $1.38 and a 1-year high of $9.26. The company has a market cap of $294.50 million, a price-to-earnings ratio of -1.95 and a beta of 1.86. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.78 and a quick ratio of 1.78. The stock has a 50 day simple moving average of $2.67 and a 200-day simple moving average of $2.72.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Thursday, March 5th. The biotechnology company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.24. The company had revenue of $39.73 million during the quarter, compared to analyst estimates of $12.02 million. BioCryst Pharmaceuticals had a negative net margin of 222.99% and a negative return on equity of 4,223.68%. Analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.98 earnings per share for the current fiscal year.
BioCryst Pharmaceuticals Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.
Further Reading: Current Ratio
Receive News & Ratings for BioCryst Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
